Experienced in Peripheral T-Cell Lymphoma

Dr. Wyndham H. Wilson

Oncology

Bethesda, MD

Clinical Trials:Currently Recruiting for 2 Trials

44 Years of Experience

Experienced in Peripheral T-Cell Lymphoma

Bethesda, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

His clinical research consists of co-authoring 167 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 2 clinical trials in the study of Peripheral T-Cell Lymphoma.

Specialties

Oncology

Licenses

Internal Medicine in WV

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

Bethesda, MD 20892

Call: 301-435-2415

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Enrollment Status: Recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Biological

Study Drugs: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid

Study Phase: Phase 1/Phase 2

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol

Enrollment Status: Recruiting

Publish Date: September 30, 2025

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma

Enrollment Status: Completed

Publish Date: June 22, 2025

Intervention Type: Diagnostic test, Drug, Other, Procedure, Biological

Study Drugs: EPOCH, Rituximab

Study Phase: Phase 2

Treatment and Natural History Study of Lymphomatoid Granulomatosis

Enrollment Status: Completed

Publish Date: June 19, 2025

Intervention Type: Biological, Diagnostic test, Drug, Procedure

Study Drugs: IFN-Alpha, Rituximab, EPOCH

Study Phase: Phase 2

Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug, Biological

Study Drugs: Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells

Study Phase: Phase 1

Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas

Enrollment Status: Completed

Publish Date: September 04, 2024

Intervention Type: Drug, Biological

Study Drugs: Rituximab, filgrastim, EPOCH

Study Phase: Phase 2

A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma

Enrollment Status: Completed

Publish Date: October 05, 2023

Intervention Type: Drug, Other

Study Drug: Ruxolitinib Phosphate

Study Phase: Phase 2

Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma

Enrollment Status: Completed

Publish Date: January 31, 2023

Intervention Type: Biological, Drug

Study Drugs: EPOCH-R, GM-CSF, Idiotype Vaccine

Study Phase: Phase 2

View 6 Less Clinical Trials

172 Total Publications

The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Journal: British journal of haematology

Published: March 28, 2025

View All 172 Publications

Similar Doctors

Advanced in Peripheral T-Cell Lymphoma

Dr. Khaled El-Shami

Oncology | Hematology

Advanced in Peripheral T-Cell Lymphoma

Dr. Khaled El-Shami

Oncology | Hematology

Johns Hopkins University

5255 Loughboro Rd Nw, Sibley Memorial Hospital,

Washington, DC

(3.1 miles away)

202-660-6500

Languages Spoken:

English

See accepted insurances

Khaled El-Shami is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. El-Shami is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Advanced in Peripheral T-Cell Lymphoma

Dr. Nina D. Wagner-Johnston

Oncology | Hematology

Advanced in Peripheral T-Cell Lymphoma

Dr. Nina D. Wagner-Johnston

Oncology | Hematology

Johns Hopkins University

8600 Old Georgetown Rd,

Bethesda, MD

(1.3 miles away)

301-896-3100

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Nina Wagner-Johnston is an Oncologist and a Hematologist in Bethesda, Maryland. Dr. Wagner-Johnston is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wagner-Johnston is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma

Dr. Richard L. Piekarz

Oncology

Advanced in Peripheral T-Cell Lymphoma

Dr. Richard L. Piekarz

Oncology

10 Center Dr Msc 1903,

Bethesda, MD

(0.1 miles away)

301-402-3524

Languages Spoken:

English

Richard Piekarz is an Oncologist in Bethesda, Maryland. Dr. Piekarz is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, and Non-Hodgkin Lymphoma.

VIEW MORE PERIPHERAL T-CELL LYMPHOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilson's expertise for a condition

ConditionClose